Main description:

Synthetic drugs, as opposed to natural drugs, are chemically produced in a laboratory. Their chemical structure can be either identical to or different from naturally occurring drugs, and their effects are designed to mimic or even enhance those of natural drugs. When produced clandestinely, they are not typically controlled pharmaceutical substances intended for legitimate medical use. Designer drugs are a form of synthetic drugs. They contain slightly modified molecular structures of illegal or controlled substances, and they are modified in order to circumvent existing drug laws. While the issue of synthetic drugs and their abuse is not new, the 112th Congress has demonstrated a renewed concern with the issues. This book provides an overview of current trends in select synthetic cannabinoids and stimulants, and reviews relevant legislation in the 112th Congress as well as issues for policy-makers.

Contents:

Preface; Synthetic Drugs: Overview & Issues for Congress; Statement of Senator Dianne Feinstein. Hearing on "Dangerous Synthetic Drugs"; Statement of Senator Charles Grassley. Hearing on "Dangerous Synthetic Drugs"; Statement of Joseph T Rannazzisi, DEA Deputy Assistant Administrator. Hearing on "Dangerous Synthetic Drugs"; Statement of Erica Leary, Program Manager, North Coastal Prevention Coalition. Hearing on "Dangerous Synthetic Drugs"; Statement of Mike Rozga. Hearing on "Dangerous Synthetic Drugs"; Affidavit of Anthony J Scalzo, MD. Hearing on "Dangerous Synthetic Drugs"; U.S. Drug Enforcement Administration, Office of Diversion Control. National Forensic Laboratory Information System Special Report: Synthetic Cannabinoids & Synthetic Cathinones Reported in NFLIS, 2009-2010; NIDA InfoFacts: Spice; JWH-018 1-Pentyl-3-(1-naphthoyl)indole.